Key Highlights

  • Third-quarter 2026 Revenue was USD 1.62 million, against USD 1.30 million a year earlier.
  • Net income per share was USD 0.29 for the quarter, against USD 0.63 last year.
  • Cash and cash equivalents were USD 2.84 million at September 30, 2026.
  • Cost of revenues decreased 14%, which the company linked to an IEEPA tariffs refund.

Arcadia Biosciences (NASDAQ:RKDA) reported third-quarter 2026 revenue of USD 1.62 million, against an estimate of USD 2.40 million. Net Income per share was USD 0.29, against an estimate of a loss of USD 0.46. The Nasdaq Capital Market-listed company sells Zola coconut water products and describes its aim as driving innovation in consumer goods.

The company said it acquired the Assets of Zola in May 2021 and has since offered consumers coconut water products positioned around rehydration. It previously developed products mainly in wheat, commercialized through food sales, trait licensing and Royalty agreements.

Results for the Quarter

Product revenues for the three months ended September 30, 2026 were USD 1,619 thousand, against USD 1,302 thousand in the same period of 2025. For the nine months, product revenues were USD 4,162 thousand, against USD 3,957 thousand. Cost of revenues was USD 760 thousand for the quarter and USD 2,272 thousand for the nine months, against USD 884 thousand and USD 2,389 thousand a year earlier.

The filing says cost of revenues decreased by USD 124,000, or 14%, during the quarter despite a year-over-year increase in sales, due to an IEEPA tariffs refund of approximately USD 175,000 received in July 2026. For the nine months, it reports a decrease of USD 117,000, or 5%, also attributed to the refund.

Selling, general and administrative expenses were USD 1,698 thousand for the quarter, against USD 1,570 thousand. The filing reports an increase of USD 128,000, or 8%, and attributes it to expenses tied to the timing of the 2026 annual Shareholder meeting, which was held in the third quarter of 2026, against the fourth quarter of 2025 for the prior-year meeting. For the nine months, the filing reports that selling, general and administrative expenses decreased by USD 1.4 million, driven by the absence of M&A expenses and lower employee costs.

Non-Operating Items and Per-Share Results

Net income attributable to common stockholders was USD 1,755 thousand for the third quarter, against USD 856 thousand a year earlier. Basic and diluted net income per share were both USD 0.29, against USD 0.63 basic and USD 0.62 diluted in the prior-year quarter. Weighted-average basic shares were 6,065,211, against 1,367,192.

The statement of operations lists a change in Fair Value of common stock Warrant and option liabilities of USD 2,574 thousand in the quarter, against USD 560 thousand a year earlier. For the nine months, the company reported a net loss attributable to common stockholders of USD 8,896 thousand, or USD 2.39 per share, against a net loss of USD 1,003 thousand, or USD 0.73 per share. The nine-month figures include a loss on the January 2026 Inducement Offer of USD 2,877 thousand, a valuation loss on the June 2026 PIPE of USD 5,423 thousand, a change in fair value of warrant and option liabilities of USD 6,848 thousand and issuance and offering costs of USD 1,072 thousand.

Cash, Financing and Balance Sheet

Cash and cash equivalents were USD 2,844 thousand at the end of the nine-month period, against USD 1,120 thousand a year earlier and USD 259 thousand at the start of 2026. Net cash provided by financing activities was USD 5,282 thousand for the nine months. It consisted of gross proceeds of USD 4.0 million from the June 2026 PIPE and USD 2.1 million from the January 2026 Inducement Offer, offset by offering cost payments of USD 450,000 and USD 350,000 respectively.

Total assets were USD 4,716 thousand at September 30, 2026, against USD 6,546 thousand at December 31, 2025. Total liabilities were USD 2,313 thousand, including USD 1,040 thousand of common stock warrant and option liabilities, and total stockholders' Equity was USD 2,403 thousand, against USD 4,140 thousand. The accumulated Deficit stood at USD 290,113 thousand. For the twelve months ended December 31, 2025, the company reported a net loss of USD 2.3 million and net cash used in operations of USD 4.7 million.